Letermovir
Prophylaxis of cytomegalovirus (CMV) infection in adult recipients of allogeneic hematopoietic stem cell transplant
- CAS No.
- 917389-32-3
- Indication Class
- Anti-infectives
- Patent Expiry
- Off-patent · 2026 (indicative)
- Therapeutic Area
- Anti-infective / Transplant
- Labeled Purity
- 98%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- 4 key intermediates available
- Patent Scope
- US / EU compound patent
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherListing Logic · Why It's Worth Listing
A first-in-class CMV terminase inhibitor replacing older ganciclovir-class agents with a better safety profile; a niche, high-value specialty API with limited competition.
Anti-infective / Transplant · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
4 key intermediates available; scale-up and cost control manageable
Product Description
Letermovir is a first-in-class antiviral medication designed to prevent cytomegalovirus (CMV) infection in adults who have received an allogeneic hematopoietic stem cell transplant (HSCT).
Supply source: Unibest · Letermovir, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.